---
title: "Saint InBio SGB-7342 (INHBE siRNA) completes first subject dosing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272356237.md"
description: "36Kr learned that on January 13, Shengyin Biotech announced that its self-developed small interfering RNA (siRNA) candidate drug SGB-7342 completed the first subject dosing in a Phase 1 clinical study for the treatment of obesity at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single-dose escalation Phase 1 clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGB-7342 in overweight and obese patients"
datetime: "2026-01-13T03:51:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272356237.md)
  - [en](https://longbridge.com/en/news/272356237.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272356237.md)
---

# Saint InBio SGB-7342 (INHBE siRNA) completes first subject dosing

36Kr learned that on January 13, Shengyin Biotech announced that its self-developed small interfering RNA (siRNA) candidate drug SGB-7342 completed the first subject dosing in a Phase 1 clinical study for the treatment of obesity at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single-dose escalation Phase 1 clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGB-7342 in overweight and obese patients

## Related News & Research

- [Hummingbird Diagnostics to Present New Findings Linking Ribosome Quality Control Pathway to Liquid Biopsy Biomarkers for Lung Cancer at EACR](https://longbridge.com/en/news/288389421.md)
- [11:35 ETEssentia Organic Mattress Unveils the World's First Biologically Engineered Sleep System at the 2026 BEYOND Biohacking Conference](https://longbridge.com/en/news/288602960.md)
- [Foundation Medicine and SWOG Clinical Trials Partnerships Announce Strategic Collaboration to Advance Biomarker-Driven Research and Clinical Trials](https://longbridge.com/en/news/288296979.md)
- [06:38 ETREJUVANT OUTPERFORMS ALL TESTED SUPPLEMENTS, INCLUDING STANDARD AKG AND NAD+ IN LANDMARK AGING CELL STUDY](https://longbridge.com/en/news/287901902.md)
- [New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer](https://longbridge.com/en/news/287874138.md)